We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
MarketsFlow is a London and Boston based, highly innovative and performance driven Investment Manager platform. It is authorised regulated by the FCA, FRN 792373 and SEC. The company supports its clients to achieve financial goals by helping their money grow. In 2019, MarketsFlow became the winner of the Best Programmatic Trading Technology at WSL and Fund in New York for the third year in a row. MarketsFlow offers Managed Portfolios (GIA), IRAs and ISAs. The company is expecting that its Growth and High Growth portfolio is accessible. In the coming months, the company is about to launch its new mobile application to complement its Growth using M&A deals.
days to go: Expired investment: £636,330
Littledata is a simpler way for companies to understand online customer conversion. Littledata's artificial intelligence sift through thousands of data series, including benchmarks or similar websites so they can alert managers to changes with the greatest commerical impact.
days to go: Expired investment: £18,760
Flender is a social lending platform that will transform the way people use peer-2-peer finance. From funding friends to backing businesses across multiple countries Flender has taken a mobile first approach. Flender allows the borrower and the lender to set their own interest rates, as well as allowing users to lend to people they know.
days to go: Expired investment: £501,700
Kalendit removes the middleman (agencies) and provides UK nurseries with temporary staff while helping them save up to 50% on staffing fees. Since September, over 150 users joined Kalendit, and it is continuing to add about two workers daily. This company had launched its services in November with four nurseries, and since then, have been successfully processed 49 bookings. With the funds raised, it will hire people and serve thirty nurseries in one year.  By the fifth year, it wants to take 45% of the London market, which equates to 1400 nurseries.
days to go: Expired investment: £82,180
Founded in 2015, Developing Experts is a complete online curriculum solution for children aged between the age group of 4 to 14 years. Developing Experts provides over 700 online lessons with a practical investigation, easy-to-understand handouts, interactive assessments and quizzes for multiple curricula including the National Curriculum. Additionally, with an aim to enhance child’s critical thinking and learning outcomes, it provides specialised lessons held by experts from the university and industry, specifically operational in science field.
days to go: Expired investment: Withheld
The SidebySide Partnership is a London based Enterprise Investment Scheme (EIS) Venture Capital (VC) firm. Its purpose is to finance and control the management teams of its investee companies enabling them to become a developed corporate entity. The SidebySide Partnership's focus is on fast-growing technology businesses with £1 - 10 million in revenue. It provides 100% EIS relief on investment with zero initial/ongoing fees charged to investors. The SidebySide Partnership's investment experience of 20+ corporate acquisitions totalling more than $200 million, 20+ private investments, and a rate of interest of 12x over the last 35 years has enabled it to become a dependable platform for upcoming tech businesses. It will use the investment to grow its business across different verticals.

Pitch Rated

43%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,500,000
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph